

**Maricopa Integrated Health Systems
Formulary Prior Auth Criteria**

Drug: Pulmozyme (Dornase Alfa, Dnase)

Therapy:

Is indicated for patients with Cystic fibrosis to reduce the risk and frequencies of serious respiratory tract infections requiring parenteral antibiotics and to improve pulmonary function. This is in combination with other standard therapies in the management of CF patients

Unlabeled use- Children with multiple hospital admissions that have required parenteral antibiotics due to frequencies of serious respiratory tract infections. To be used in conjunction with other treatment modalities. This will be on a case by case basis

Inclusions:

- 1) Diagnosis
- 2) Patient have a forced vital capacity (FVC) greater than or equal to 40% of the predicted value
- 3) Request comes from a pulmonary specialist

Additional information

Dose- 2.5ml single use ampule inhaled once daily using a recommended nebulizer

Authorization:

Three months initially and one year with documented efficacy

Medical Director _____

Date _____